C92.62 ICD-10-CM Code: Acute myeloid leukemia with 11q23-abnormality in relapse
HCC Buddy Code Card
Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.
FY 2026 Apr update / Neoplasms (C00-D49) / Malignant neoplasms of lymphoid, hematopoietic and related tissue (C81-C96)
C92.62
Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidanceAcute myeloid leukemia with 11q23-abnormality in relapse
A specific type of acute myeloid leukemia with a chromosomal abnormality (11q23) where the cancer has returned after a period of remission.
Buddy Insight
Acute myeloid leukemia with 11q23-abnormality in relapse indicates recurrence of this cytogenetically defined AML subtype after prior remission.
CMS-HCC V28
MappedHCC 17
RAF 0.368
CMS-HCC V24
MappedHCC 8
RAF 2.484
ACA/HHS
00
RAF 0
ESRD/PACE
MappedHCC 8
RAF 0.0
RXHCC
MappedHCC 19
RAF 0.0
Code Trumping
Basket needed
Code Book Path
Inclusion Terms
Official- Acute myeloid leukemia with variation of MLL-gene
Excludes 2
OfficialICD-10-CM does not list Excludes 2 notes for C92.62 in this effective period.
Related Child Codes
Includes
OfficialICD-10-CM does not list Includes notes for C92.62 in this effective period.
Excludes 1
OfficialICD-10-CM does not list Excludes 1 notes for C92.62 in this effective period.
Code First
OfficialICD-10-CM does not list Code First sequencing instructions for C92.62 in this effective period.
Use Additional
OfficialICD-10-CM does not list Use Additional Code instructions for C92.62 in this effective period.
Code Also
OfficialICD-10-CM does not list Code Also instructions for C92.62 in this effective period.
Buddy Documentation Tip
MEAT Support
Audit Caution
Common Mistakes
Last updated: FY2026 ICD-10-CM Apr update, Apr 1, 2026 through Sep 30, 2026. CMS-HCC V28 is 100% phased in for payment year 2026.
Is C92.62 an HCC code?
Yes. C92.62 maps to Metastatic Cancer and Acute Leukemia under the CMS-HCC V28 risk adjustment model (and Metastatic Cancer and Acute Leukemia under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for C92.62
For C92.62to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically, it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C92.62 during that encounter, not just copy-forwarded from a problem list.
What This Code Means
C92.62 is the ICD-10-CM diagnosis code for acute myeloid leukemia with 11q23-abnormality in relapse. A specific type of acute myeloid leukemia with a chromosomal abnormality (11q23) where the cancer has returned after a period of remission. C92.62 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of lymphoid, hematopoietic and related tissue (c81-c96).
Under the CMS-HCC V28 risk adjustment model, C92.62 maps to Metastatic Cancer and Acute Leukemia (HCC 17) with a community, non-dual, aged base RAF weight of 0.368. Under the older V24 model, C92.62 mapped to the same category but with a base RAF weight of 2.484, V28 recalibrated weights across the entire model. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Document both the cytogenetic abnormality and the relapse status in the medical record. Because C92.62 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C92.62 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Document both the cytogenetic abnormality and the relapse status in the medical record
- •Distinguish between initial presentation and relapse based on treatment history
Clinical Significance
Acute myeloid leukemia with 11q23-abnormality in relapse indicates recurrence of this cytogenetically defined AML subtype after prior remission. Relapsed AML with 11q23 rearrangements carries a poor prognosis, though outcomes vary by the specific fusion partner. Salvage therapy followed by allogeneic stem cell transplantation offers the best chance for long-term survival in eligible patients.
Documentation Requirements
- ✓Documentation must confirm prior remission and relapse with the 11q23/KMT2A rearrangement, ideally confirmed at relapse as clonal evolution may occur.
- ✓Duration of first remission, prior treatment regimens, and updated molecular/cytogenetic testing at relapse must be recorded.
- ✓Transplant candidacy assessment, donor search status, and salvage treatment plan should be documented.
Commonly Confused Codes
- •C92.60 (AML with 11q23 not in remission) is for primary refractory disease.
- •C92.61 (AML with 11q23 in remission) is for controlled disease.
- •C92.02 (AML in relapse) is less specific and does not capture the cytogenetic abnormality.
- •C92.52 (AMML in relapse) may overlap clinically but does not specify the 11q23 abnormality.